132 related articles for article (PubMed ID: 12908490)
21. Safety of calcium channel blockers for hypertension questioned.
Health News; 2005 Apr; 11(4):5. PubMed ID: 15818763
[No Abstract] [Full Text] [Related]
22. Initial therapy of hypertension.
Med Lett Drugs Ther; 2004 Jul; 46(1186):53-5. PubMed ID: 15237281
[No Abstract] [Full Text] [Related]
23. [Drug-induced taste disorders].
Meyer D; Hartmann K; Kuhn M
Praxis (Bern 1994); 1996 Nov; 85(46):1468-72. PubMed ID: 8984568
[TBL] [Abstract][Full Text] [Related]
24. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
Landmark K; Reikvam A
Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
[TBL] [Abstract][Full Text] [Related]
25. [Industrial dysgeusia].
Pihrt J
Cesk Otolaryngol; 1980 Aug; 29(4):232-5. PubMed ID: 7408004
[No Abstract] [Full Text] [Related]
26. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
[TBL] [Abstract][Full Text] [Related]
27. [Ageusia in a patient treated with carbamazepine].
Barajas García-Talavera F
Neurologia; 1988; 3(3):126-7. PubMed ID: 3078761
[No Abstract] [Full Text] [Related]
28. [Dysgeusia during treatment with enalapril].
Perronne C; Gerbaud L; Leport C; Vilde JL
Therapie; 1989; 44(1):67. PubMed ID: 2544036
[No Abstract] [Full Text] [Related]
29. [Reversible ageusia during cefacetril therapy].
Mall T; Witt M; Follath F
Dtsch Med Wochenschr; 1983 Nov; 108(44):1698. PubMed ID: 6628251
[No Abstract] [Full Text] [Related]
30. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Gojanovic B; Feihl F; Liaudet L; Waeber B
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
[TBL] [Abstract][Full Text] [Related]
31. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
32. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
de la Sierra A
J Hum Hypertens; 2009 Aug; 23(8):503-11. PubMed ID: 19148104
[TBL] [Abstract][Full Text] [Related]
33. Dysgeusia after high dose dipyridamole treatment (short communication).
Goy JJ; Finci L; Sigwart U
Arzneimittelforschung; 1985; 35(5):854. PubMed ID: 4026910
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive medications and the risk of incident type 2 diabetes: response to Taylor et al.
Gosmanov AR; Connelly S; Lewis JB; Gosmanov NR
Diabetes Care; 2006 Oct; 29(10):2334; author reply 2334-5. PubMed ID: 17003329
[No Abstract] [Full Text] [Related]
35. [Reversible loss of taste as a side effect in thiamazole therapy].
Reck R; von Mengden HJ
Fortschr Med; 1982 Mar; 100(11):444-5. PubMed ID: 7076071
[TBL] [Abstract][Full Text] [Related]
36. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
Wald DS; Law M; Morris JK; Bestwick JP; Wald NJ
Am J Med; 2009 Mar; 122(3):290-300. PubMed ID: 19272490
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).
Sidoroff A; Dunant A; Viboud C; Halevy S; Bavinck JN; Naldi L; Mockenhaupt M; Fagot JP; Roujeau JC
Br J Dermatol; 2007 Nov; 157(5):989-96. PubMed ID: 17854366
[TBL] [Abstract][Full Text] [Related]
40. Impact of ASCOT on hypertension treatment and guidelines in older adults.
Sheridan R; Baldwin N
Age Ageing; 2006 May; 35(3):214-7. PubMed ID: 16638764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
